EU APPROVES TAGRISSO FOR 1ST-LINE NSCLC
08 June 2018 17:30BST The EU approves Tagrisso for 1st-line treatment of EGFR-mutated non-small cell lung cancer 1st-line Tagrisso offers a potential new standard of care Today the European Commission has granted marketing authorisation for Tagrisso (osimertinib) as monotherapy for the 1st-line treatment of adult patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations. The approval is based on results from the Phase III FLAURA trial published in the New England Journal of